Ivan Rusyn

Dr. Ivan Rusyn


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Toxicology Research
Verified
Journal Article
Open access
PDF file
VSValerie Y. Soldatow
Valerie Y. Soldatow
ELEdward L. LeCluyse
Edward L. LeCluyse
LGLinda G. Griffith
Linda G. Griffith
IRIvan Rusyn
Ivan Rusyn
Over the years, various liver-derived in vitro model systems have been developed to enable investigation of the potential adverse effects of chemicals

1 January 2006 in Critical Reviews in Toxicology
Verified
Journal Article
Closed access
IRIvan Rusyn
Ivan Rusyn
JPJeffrey M. Peters
Jeffrey M. Peters
MCMichael L. Cunningham
Michael L. Cunningham
The industrial plasticizer di-(2-ethylhexyl)phthalate (DEHP) is used in manufacturing of a wide variety of polyvinyl chloride (PVC)-containing medical and consumer products. DEHP belongs to a class of chemicals known as peroxisome proliferators (PPs). PPs are a structurally diverse group of compounds that share many (but perhaps not all) biological effects and are characterized as non-genotoxic rodent carcinogens. This review focuses on the effect of DEHP in liver, a primary target organ for the pleiotropic effects of DEHP and other PPs. Specifically, liver parenchymal cells, identified herein as hepatocytes, are a major cell type that are responsive to exposure to PPs, including DEHP; however, other cell types in the liver may also play a role. The PP-induced increase in the number and size of peroxisomes in hepatocytes, so called ‘peroxisome proliferation' that results in elevation of fatty acid metabolism, is a hallmark response to these compounds in the liver. A link between peroxisome proliferation and tumor formation has been a predominant, albeit questioned, theory to explain the cause of a hepatocarcinogenic effect of PPs. Other molecular events, such as induction of cell proliferation, decreased apoptosis, oxidative DNA damage, and selective clonal expansion of the initiated cells have been also been proposed to be critically involved in PP-induced carcinogenesis in liver. Considerable differences in the metabolism and molecular changes induced by DEHP in the liver, most predominantly the activation of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)α, have been identified between species. Both sexes of rats and mice develop adenomas and carcinomas after prolonged feeding with DEHP; however, limited DEHP-specific human data are available, even though exposure to DEHP and other phthalates is common in the general population. This likely constitutes the largest gap in our knowledge on the potential for DEHP to cause liver cancer in humans. Overall, it is believed that the sequence of key events that are relevant to DEHP-induced liver carcinogenesis in rodents involves the following events whereby the combination of the molecular signals and multiple pathways, rather than a single hallmark event (such as induction of PPARα and peroxisomal genes, or cell proliferation) contribute to the formation of tumors: (i) rapid metabolism of the parental compound to primary and secondary bioactive metabolites that are readily absorbed and distributed throughout the body; (ii) receptor-independent activation of hepatic macrophages and production of oxidants; (iii) activation of PPARα in hepatocytes and sustained increase in expression of peroxisomal and non-peroxisomal metabolism-related genes; (iv) enlargement of many hepatocellular organelles (peroxisomes, mitochondria, etc.); (v) rapid but transient increase in cell proliferation, and a decrease in apoptosis; (vi) sustained hepatomegaly; (vii) chronic low-level oxidative stress and accumulation of DNA damage; (viii) selective clonal expansion of the initiated cells; (ix) appearance of the pre-neoplastic nodules; (x) development of adenomas and carcinomas.

5 March 2018 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
SMSkylar W. Marvel
Skylar W. Marvel
KTKimberly To
Kimberly To
FGFabian Alexander Grimm
Fabian Alexander Grimm
FWFred Wright
Fred Wright
IRIvan Rusyn
Ivan Rusyn
David ReifDavid Reif
David Reif
Drawing integrated conclusions from diverse source data requires synthesis across multiple types of information. The ToxPi (Toxicological Prioritization Index) is an analytical framework that was developed to enable integration of multiple sources of evidence by transforming data into integrated, visual profiles. Methodological improvements have advanced ToxPi and expanded its applicability, necessitating a new, consolidated software platform to provide functionality, while preserving flexibility for future updates. We detail the implementation of a new graphical user interface for ToxPi (Toxicological Prioritization Index) that provides interactive visualization, analysis, reporting, and portability. The interface is deployed as a stand-alone, platform-independent Java application, with a modular design to accommodate inclusion of future analytics. The new ToxPi interface introduces several features, from flexible data import formats (including legacy formats that permit backward compatibility) to similarity-based clustering to options for high-resolution graphical output. We present the new ToxPi interface for dynamic exploration, visualization, and sharing of integrated data models. The ToxPi interface is freely-available as a single compressed download that includes the main Java executable, all libraries, example data files, and a complete user manual from http://toxpi.org .

1 April 2016 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
GCGrace Chappell
Grace Chappell
IPIgor P. Pogribny
Igor P. Pogribny
KGKathryn Z. Guyton
Kathryn Z. Guyton
IRIvan Rusyn
Ivan Rusyn


2 September 2014 in Current Protocols in Pharmacology
Verified
Journal Article
Open access
PDF file
TUTakeki Uehara
Takeki Uehara
IPIgor P. Pogribny
Igor P. Pogribny
IRIvan Rusyn
Ivan Rusyn
Human hepatocellular carcinoma (HCC) develops most often as a complication of fibrosis or cirrhosis. While most human studies of HCC provide crucial insights into the molecular signatures of HCC, seldom do they address the etiology of HCC. Mouse models are essential tools for investigating the pathogenesis of HCC; however, the overwhelming majority of cancer models in rodents do not feature liver fibrosis. Detailed in this unit is a protocol for an experimental mouse model of HCC that arises in association with advanced liver fibrosis. The disease model is induced by a single injection of N‐nitrosodiethylamine (DEN) followed by repeated administration of carbon tetrachloride (CCl4). A dramatic potentiation of liver tumor incidence is observed following administration of DEN and CCl4, with100% of mice developing liver tumors at 5 months of age. This model can be employed for studying the molecular mechanisms of fibrogenesis and HCC development, and in cancer hazard/chemotherapy testing of drug candidates. Curr. Protoc. Pharmacol. 66:14.30.1‐14.30.10. © 2014 by John Wiley & Sons, Inc.